Survival Outcomes of Uterine Cervical Malignancies in Chinese Population

• Sponsor: Lei Li (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT03291236
• Collaborator: (none)
• Enrollment: 5,000
• Location: 1
• Anticipated Duration (Months): 72
• Patients Per Site Per Month: 69.5

Study Details

Study Description

Brief Summary

This study aims to determine survival outcomes (overall survival and progression-free survival) of primary malignancies of uterine cervix in China and relevant risk factors in a prospective cohort study.

Condition or Disease	Intervention/Treatment	Phase
Uterine Cervical Neoplasms; Survival	Other: Follow-up for death and recurrence of patients

Study Design

• Study Type: Observational
• Anticipated Enrollment: 5000 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Survival Outcomes of Uterine Cervical Malignancies in Chinese Population
• Actual Study Start Date: Jan 1, 2017
• Anticipated Primary Completion Date: Jan 1, 2022
• Anticipated Study Completion Date: Jan 1, 2023

Outcome Measures

Primary Outcome Measures

1. Overall survival [5 years]

   Duration from diagnosis to recurrence

2. Progression-free survival [5 years]

   Duration from last treatment after remission to recurrence

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Primary malignancies of uterine cervix.

Exclusion Criteria:

• Secondary malignancies of uternie cervix.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Lei Li	Beijing	China/Beiing	China	100000

Sponsors and Collaborators

• Lei Li

Investigators

• Principal Investigator: Lei Li, MD, Peking Union Medical College Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Lei Li, Professor, Peking Union Medical College Hospital
• ClinicalTrials.gov Identifier: NCT03291236
• Other Study ID Numbers: SOCM-1
• First Posted: Sep 25, 2017
• Last Update Posted: Feb 8, 2018
• Last Verified: Feb 1, 2018

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Uterine Cervical Neoplasms

Study Results

No Results Posted as of Feb 8, 2018